Effect of XXXX on blood pressure, plasma @entity2661 and plasma @entity916 activity in essential @entity101 .

@entity1 @entity101 @entity31769 @entity918 @entity4 @entity2661 @entity6478 @entity1296 @entity916 @entity10 @entity1706
@entity1706 , a new @entity31769 derivative, is an antihypertensive agent with arteriolar vasodilating properties, which acts on precapillary resistance vessels. A trial was carried out in 30 @entity1 with essential @entity101 WHO I-II. The treatment period was divided into three phases. @entity918 ( @entity918 ) and @entity6478 were administered for 4 weeks in Phase 1 and supine and standing blood pressure decreased significantly. During Phase 2 @entity1706 was added to @entity918 / @entity6478 for the following 3 months. A further significant reduction in blood pressure was obtained. In the next period of treatment (Phase 3) @entity1 were divided into two groups. For 1 month Group A (15 @entity1 ) received @entity1706 alone and Group B (15 @entity1 ) received @entity918 / @entity6478 . Conventional laboratory blood tests in all @entity1 remained unchanged during treatment. Reported side effects during Phase 2 were @entity10 (2 @entity1 ), @entity1296 (3 @entity1 ), palpitations (2 @entity1 ) and ankle @entity4 (2 @entity1 ). Plasma @entity916 activity was slightly increased at the end both of Phases 1 and 2. Plasma @entity2661 were increased but not significantly at the end of Phase 2 as compared to Phase 1. The results indicate that @entity1706 is effective in lowering blood pressure in mild to moderate essential @entity101 .
